A Multicenter Trial Assessing the Efficacy and Safety of tamOxifen Plus LY2228820 in Advanced or Metastatic Breast Cancer Progressing on aromatasE Inhibitors

NCT02322853 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Stopped lack of recruitment

Conditions

Postmenopausal
Metastatic Breast Cancer

Interventions

DRUG: Tamoxifen
DRUG: Ralimetinib (LY2228820 dimesylate)

Sponsor

Centre Francois Baclesse

Collaborators

[object Object]
[object Object]